Key result
Rivaroxaban was associated with a lower risk of non-persistence (aHR 0.89; 95% CI 0.84-0.95) and discontinuation (aHR 0.71; 95% CI 0.66-0.77) compared to dabigatran in patients with NVAF.
Why the study?
Does rivaroxaban improve medication persistence and reduce discontinuation compared to dabigatran in patients with non-valvular atrial fibrillation?
Cohort (n=30,337)
Yes
Does rivaroxaban improve medication persistence and reduce discontinuation compared to dabigatran in patients with non-valvular atrial fibrillation?
Hazard Ratio: 0.89 (95% CI 0.84–0.95)
In real-world practice, rivaroxaban is associated with better medication persistence and lower discontinuation rates compared to dabigatran in patients with non-valvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Observational persistence differences in NVAF may inform selection; leaves open outcome impact.
Nelson et al. (2015) conducted a cohort in non-valvular atrial fibrillation (n=30,337). Rivaroxaban vs. Dabigatran was evaluated on Non-persistence with therapy (HR 0.89, 95% CI 0.84-0.95). Rivaroxaban was associated with a lower risk of non-persistence (aHR 0.89; 95% CI 0.84-0.95) and discontinuation (aHR 0.71; 95% CI 0.66-0.77) compared to dabigatran in patients with NVAF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: